Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels.
RHAPSODY was the first well-powered clinical trial to show the positive risk-benefit ratio of 5-grass-pollen SLIT drops in adult participants with moderate-to-severe grass-pollen-induced ARC.
Symptomatic efficacy of opicapone was maintained with 1-year open-label treatment (adjusted-mean ± SE change in MDS-UPDRS motor score from gold-standard blind baseline to Week 76: -7.4 ± 0.81); participants who switched from...
Prophylactic LMWH started at diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration.
XXL was a compared against a dummy pill (placebo) phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit).
Over 24 weeks, 91% of patients achieved complete terminal complement inhibition with crovalimab.
These data indicate that the studied doses of linezolid and moxifloxacin could be the right balance between effectiveness and safety, strengthening the WHO recommendation that BPaLM is the preferred regimen for...
Of 31 participants screened, 22 were randomized; 1 placebo-assigned participant did not meet the NRS ≥5 criterion and was excluded, leaving 21 for analysis (IFT: 11; placebo: 10).
Study results suggested adding parsaclisib to stable-dose ruxolitinib was unlikely to offer clinically meaningful benefits.
We elicited a prior distribution that incorporated past evidence and expert opinion.
Higher risk of neutropenia was associated with lower baseline absolute neutrophil count and lower baseline body weight.
Compared with data on standard-dose tamoxifen, rates of benign events were lower.
Evaluation of ctDNA in resected stage III CC using a tissue-free assay provided robust and independent prognostic value.
Adding zoledronic acid did not improve clinical outcomes in ES.
BCG + MM was not proved superior to BCG alone, but required 39% fewer doses of BCG and fewer treatment discontinuations.
In this secondary analysis of the SPARTAN trial, statin use was not associated with improved survival outcomes overall.
In ELATIVE, lower baseline ALP correlated with higher biochemical response and ALP normalization rates with elafibranor.
With a comparable safety profile across treatment groups, these findings suggest that TEL/AML 20/2.5 is a practical and effective option for high blood pressure management.
Nipocalimab treatment improves gMG symptoms earlier than placebo and provides meaningful and long-term sustained disease control over 24 weeks among participants with gMG.
The developed model adequately characterized leuprolide how the body absorbs the medicine in pediatrics.
Patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups receiving vunakizumab show a favourable clinical response, regardless of achieving early response or not.
NTCP models for acute and late diarrhea and persistent GI toxicity after postoperative radiotherapy for cervical cancer included bowel V30Gy and V40Gy.
Single-pill LDC-ALC achieved BP reductions similar to those with amlodipine and greater than those with losartan single-drug treatment over 8 weeks, with similar short-term tolerability.
In GALACTIC-HF, higher DP levels were independently associated with increased risk of adverse clinical outcomes in patients with reduced ejection fraction.
In addition to significant improvement on five out of eight Marder Positive Symptom items, the following non-Positive PANSS items were notable for being especially responsive to lurasidone treatment in terms of significant...
This is the only heart and blood vessel outcomes trial to date that exclusively enrolled patients with statin intolerance, and the largest contemporary study of lipid lowering therapy in females, a group historically...
Single dose AQST-109 demonstrated PK exposures consistently bracketed within established levels for approved intramuscular epinephrine and autoinjectors, with a more rapid time-to-maximum plasma concentration and comparable PD...
An integrated WASH intervention delivered in the absence of mass antibiotic distributions did not reduce clinical trachoma outcomes in an area with hyperendemic trachoma.
Although the primary endpoint was not met, the data provide important information on baricitinib for the treatment of children with JIA-U refractory to both MTX and bDMARDs.
BEAM is a highly scalable intervention that has the potential to rapidly reach underserved groups in need of mental health and parenting support.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
